News & Press: Advocacy

SIS Comments on Regence Blue Cross Blue Shield’s Coverage Denial of HF10 SCS Therapy

Monday, February 6, 2017  
Share |
Counter to controlled studies, Regence Blue Cross Blue Shield issued policy number 45: Spinal Cord and Dorsal Root Ganglion Stimulation Medical Policy, that designates high frequency spinal cord stimulation therapy (HF10) as investigational and not covered.
 
On February 3, 2017, the Spine Intervention Society submitted comments to Regence highlighting evidence for the efficacy of HF10 therapy and requested a 24-month delay in the implementation of the policy to allow for further evidence to be published and considered. SIS is also currently addressing this issue with Blue Cross Blue Shield of Massachusetts, as described here.

Contact Us

120 E. Ogden Ave. Ste. 202
Hinsdale, Illinois 60521
P: 630.203.2252
Toll Free: 888.255.0005

© Copyright 2016 Spine Intervention Society Privacy Policy  ::  Legal